The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Day One Biopharmaceuticals Inc’s stock clocked out at $13.49, up 1.43% from its previous closing price of $13.30. In other words, the price has increased by $1.43 from its previous closing price. On the day, 0.56 million shares were traded. DAWN stock price reached its highest trading level at $13.655 during the session, while it also had its lowest trading level at $13.12.
Ratios:
To gain a deeper understanding of DAWN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.09 and its Current Ratio is at 4.09. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 01, 2024, Upgraded its rating to Buy and sets its target price to $24 from $11 previously.
On April 24, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $30 to $33.
BofA Securities Downgraded its Buy to Underperform on April 25, 2023, whereas the target price for the stock was revised from $34 to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 16 ’24 when Blackman Samuel C. sold 20,000 shares for $16.01 per share. The transaction valued at 320,226 led to the insider holds 1,121,081 shares of the business.
Ramasastry Saira sold 10,000 shares of DAWN for $131,877 on Jun 21 ’24. The Director now owns 40,485 shares after completing the transaction at $13.19 per share. On Jun 10 ’24, another insider, Blackman Samuel C., who serves as the HEAD OF R&D of the company, sold 30,000 shares for $12.62 each. As a result, the insider received 378,588 and left with 1,141,081 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1326231552 and an Enterprise Value of 822212544. For the stock, the TTM Price-to-Sale (P/S) ratio is 144.55 while its Price-to-Book (P/B) ratio in mrq is 3.86. Its current Enterprise Value per Revenue stands at 100.368 whereas that against EBITDA is -2.863.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $9.67. The 50-Day Moving Average of the stock is -3.38%, while the 200-Day Moving Average is calculated to be -5.13%.
Shares Statistics:
It appears that DAWN traded 986.25K shares on average per day over the past three months and 1453680 shares per day over the past ten days. A total of 87.23M shares are outstanding, with a floating share count of 60.89M. Insiders hold about 30.61% of the company’s shares, while institutions hold 70.75% stake in the company. Shares short for DAWN as of 1721001600 were 11524197 with a Short Ratio of 12.38, compared to 1718323200 on 10293130. Therefore, it implies a Short% of Shares Outstanding of 11524197 and a Short% of Float of 16.389999.
Earnings Estimates
The current rating of Day One Biopharmaceuticals Inc (DAWN) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.4 and low estimates of -$1.08.
Analysts are recommending an EPS of between -$0.79 and -$2.37 for the fiscal current year, implying an average EPS of -$1.78. EPS for the following year is -$1.8, with 10.0 analysts recommending between -$0.26 and -$4.29.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $22.31M. It ranges from a high estimate of $83M to a low estimate of $7M. As of the current estimate, Day One Biopharmaceuticals Inc’s year-ago sales were $nanFor the next quarter, 7 analysts are estimating revenue of $15.84M. There is a high estimate of $20.08M for the next quarter, whereas the lowest estimate is $9.4M.
A total of 8 analysts have provided revenue estimates for DAWN’s current fiscal year. The highest revenue estimate was $107M, while the lowest revenue estimate was $24.5M, resulting in an average revenue estimate of $44.72M. In the same quarter a year ago, actual revenue was $nanBased on 9 analysts’ estimates, the company’s revenue will be $136.25M in the next fiscal year. The high estimate is $208.2M and the low estimate is $63.49M.
